Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies (Q30955085)

27 June 2017

1 reference

title

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies (English)

1 reference

27 June 2017

1 reference

Peter Ball

1

1 reference

27 June 2017

Ralf Stahlmann

2

1 reference

27 June 2017

Rolf Kubin

3

1 reference

27 June 2017

Shurjeel Choudhri

4

1 reference

27 June 2017

Robert Owens

5

1 reference

27 June 2017

publication date

1 July 2004

1 reference

27 June 2017

published in

Clinical Therapeutics

1 reference

27 June 2017

volume

26

1 reference

27 June 2017

issue

7

1 reference

27 June 2017

page(s)

940-950

1 reference

Fluoroquinolone adverse effects and drug interactions

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Safety of the new fluoroquinolones compared with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Temafloxacin syndrome: review of 95 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

New milestones achieved in fluoroquinolone safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Possible gatifloxacin-induced hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

The QT interval and torsade de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Long QT syndromes and torsade de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Quinolone-induced QT interval prolongation: a not-so-unexpected class effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Cardiotoxicity of fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Rate-corrected QT interval: techniques and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Drug interactions with cisapride: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

QT prolongation with antimicrobial agents: understanding the significance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

The effects of quinolones on xanthine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Profile of moxifloxacin drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

Fluoroquinolones in the elderly: safety considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990170-1

7 January 2021

10.1016/S0149-2918(04)90170-1

Identifiers

DOI

1 reference

27 June 2017

1 reference